YOLFTbeta
Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

INBX · NASDAQ · Healthcare / Biotechnology

83.30USD-4.45 (-5.07%)

Price History

Full chart

Market Stats

Previous Close87.75
Open87.91
Day Range80.68 – 87.91
52-Week Range28.16 – 155.29
Volume245.42K
Market Cap1.47B
P/E (TTM)0.00
Forward P/E0.00
EPS-8.88
Dividend Yield0.00%
Beta3.67
50-Day Avg100.55
200-Day Avg90.62

About

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Mark Paul Lappe
  • Employees109
  • Headquarters11025 North Torrey Pines Road, La Jolla, CA, United States, 92037, USA
  • Websitehttps://inhibrx.com

Leadership

  • Mr. Mark Paul LappeFounder, CEO & Chairman · b. 1967
  • Mr. David J. Matly M.B.A.President · b. 1986
  • Ms. Kelly Devine Deck B.S., CPA, M.S.Executive VP, CFO & Treasurer · b. 1980
  • Ms. Bonne Adams M.B.A.Vice President of Operations · b. 1977
  • Ms. Kate Burke CPA, M.B.A.Vice President of Accounting
  • Dr. Ashraf Amanullah Ph.D.Executive VP & Chief Technical Operations Officer · b. 1968
  • Dr. Carlos Bais Ph.D.EVP & Chief Scientific Officer
  • Ms. Leah Pollema J.D.VP, General Counsel & Corporate Secretary
  • Dr. Josep Garcia Ph.D.Executive VP & Chief Clinical Development Officer

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue6.67M8.39M8.60M9.09M12.81M7.13M2.19M1.80M200.00K1.30M
Growth (%)-+25.86%+2.43%+5.79%+40.86%-44.37%-69.24%-17.88%-88.89%+550.00%
Cost of Revenue16.99M25.51M33.45M47.91M73.50M2.69M110.19M1.19M2.29M2.48M
Gross Profit-10.32M-17.12M-24.86M-38.81M-60.69M4.44M-107.99M609.00K-2.08M-1.18M
Gross Margin-154.87%-204.02%-289.23%-426.86%-473.82%62.27%-4926.73%33.83%-1042.50%-91.00%
Operating Expense1.82M2.61M4.65M2.14M6.76M81.11M21.12M219.83M329.36M133.84M
Operating Income-12.15M-19.73M-29.51M-40.95M-67.44M-76.67M-129.12M-219.22M-331.45M-135.03M
Operating Margin-182.18%-235.11%-343.37%-450.38%-526.57%-1076.07%-5890.37%-12178.94%-165724.00%-10386.54%
EBITDA-11.89M-19.30M-28.77M-39.79M-66.43M-76.55M-125.82M-206.69M1.70B-125.37M
EBITDA Margin-178.39%-230.07%-334.72%-437.59%-518.63%-1074.39%-5739.83%-11482.94%851675.00%-9644.15%
Net Income-8.27M-19.44M-31.16M-51.40M-76.12M-81.77M-145.23M-241.36M1.69B-140.06M
Net Income Margin-124.03%-231.70%-362.57%-565.27%-594.35%-1147.62%-6625.27%-13408.94%843786.00%-10773.46%
R&D16.99M25.51M33.45M47.91M73.50M71.44M110.19M190.65M203.74M113.03M
R&D as % of Total Revenue254.87%304.02%389.23%526.86%573.82%1002.67%5026.73%10591.56%101871.50%8694.46%
Interest Expense-2.13M1.48M5.72M10.82M5.22M16.11M31.84M13.49M12.20M
Interest Expense % of Total Revenue-25.34%17.22%62.89%84.45%73.21%734.81%1768.89%6745.50%938.15%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets21.27M17.25M9.98M26.49M143.74M150.45M290.88M307.89M180.77M146.48M
Total Liabilities20.03M39.67M67.63M120.06M68.27M98.07M232.82M264.39M47.18M138.49M
Total Equity-9.25M-28.77M-57.64M-93.57M75.47M52.38M58.06M43.50M133.58M7.99M
Cash20.02M13.47M2.10M11.54M128.66M131.30M273.87M277.92M152.60M124.22M
Total Debt18.92M14.66M9.49M41.73M37.45M72.14M207.10M210.14M8.05M107.01M
Net Debt-1.11M1.19M7.39M30.19M-91.21M-59.16M-66.76M-67.78M-144.55M-17.21M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-18.11M-18.75M-23.09M-32.08M-47.97M-80.32M-115.30M-193.31M-194.41M-129.79M
Investing Cash Flow-215.00K-1.34M-1.43M-1.81M-1.36M-809.00K-686.00K-4.59M-2.60M-28.00K
Financing Cash Flow28.77M13.54M13.15M43.33M166.46M83.77M258.55M201.96M71.68M101.45M
Capital Expenditure215.00K1.34M1.43M1.81M1.36M864.00K686.00K4.59M2.60M31.00K
Free Cash Flow-18.32M-20.09M-24.52M-33.89M-49.33M-81.19M-115.99M-197.90M-197.01M-129.82M
Dividends Paid-1.38M828.00K-------
FCF to OCF101.19%107.15%106.19%105.64%102.84%101.08%100.59%102.38%101.34%100.02%
Dividend Paid to FCF--6.84%-3.38%-------

Earnings

Report DateMay 29, 2024Aug 13, 2024Nov 14, 2024Mar 17, 2025May 14, 2025Aug 13, 2025Nov 14, 2025Mar 23, 2026May 14, 2026Aug 13, 2026Nov 13, 2026
EPS Estimate-1.04-1.52-3.70-1.44-3.12-2.60-1.72-1.63-1.20-2.50-2.50
EPS Actual-1.44125.48-2.84-3.09-2.80-1.85-2.28-2.11-2.15-2.34-
Surprise-38.46%8355.26%23.24%-114.58%10.26%28.85%-32.56%-29.45%-79.17%6.40%-
Timing--After-hours-After-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.47B
Enterprise Value1.53B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1000.46
Price / Book212.28
EPS-8.88
Book Value-3.60
Revenue (TTM)0
Gross Profit (TTM)-103.00M
EBITDA-125.60M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-1773.60%
Return on Assets-43.61%
Shares Outstanding14.72M
Shares Float8.60M
Beta3.67
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
91.07%
Insiders
23.08%
Retail / Other
0.00%

Top Institutional Holders

  • Viking Global Investors LP
    1.44M9.77%
  • Perceptive Advisors LLC
    1.30M8.82%
  • Morgan Stanley - Brokerage Accounts
    1.26M8.58%
  • Sanofi
    1.16M7.87%
  • HighTower Advisors, LLC
    870.20K5.91%
  • BlackRock Inc
    798.90K5.43%
  • State Street Corp
    550.85K3.74%
  • Vanguard Capital Management, LLC
    486.42K3.31%
  • Sofinnova Ventures
    406.03K2.76%
  • Woodline Partners LP
    384.43K2.61%
  • Capital Research Global Investors
    363.05K2.47%
  • Partner Fund Management LP
    308.38K2.10%
  • Parkman Healthcare Partners LLC
    256.95K1.75%
  • Schonfeld Strategic Advisors LLC
    254.83K1.73%
  • Geode Capital Management, LLC
    231.51K1.57%
  • HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
    170.70K1.16%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    423.25K2.88%
  • Vanguard MStar Total Stk Mkt Idx Invest
    369.64K2.51%
  • American Funds SMALLCAP World A
    353.29K2.40%
  • iShares Russell 2000 ETF
    243.45K1.65%

Dividends

20241×
0.85May 30, 2024